Gordon K Mak, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · County of San Mateo
Looking this up.
Hospitals listed: San Mateo Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mak’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A61568 · Current
Licensed to practise in California · since 1997 · expires 2029-01-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- San Mateo Medical CenterSan Mateo, CAAcute Care Hospital · Government - Local · Has an emergency departmentPart of San Mateo County HealthPatients rate it 3 of 5 · 68% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for San Mateo Medical Center
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.34 (0.25 to 2.43) · 45 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.48 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 25 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 379 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 381 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.44 (0.82 to 6.05) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.64 (0.92 to 4.37) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.53 (0 to 1.76) · 296 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.661 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.3 · 25 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.4 to 18.9) · 167 cases | No different | Jan 2022 – Dec 2024 |
What patients said (208 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$17,374
Medicare paid this office $17,374 for 159 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 77 | $7,249 | $84 |
| Return visit (30+ min) | 24 | $2,882 | $115 |
| New patient visit (45+ min) | 22 | $2,293 | $104 |
| Test to determine lung volumes using sensors | 26 | $229 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 27 | $205 | $8 |
See all 6 services
| Return visit (30+ min) | 77 | $7,249 | $84 |
| Return visit (30+ min) | 24 | $2,882 | $115 |
| New patient visit (45+ min) | 22 | $2,293 | $104 |
| Test to determine lung volumes using sensors | 26 | $229 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 27 | $205 | $8 |
| Test to examine how well the lungs exchange gases | 26 | $170 | $7 |
Who their Medicare patients are
159 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 14% · Women 59% · Also on Medicaid 45% · Health risk score 1.75. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 55% · Coronary heart disease 42% · Diabetes 32% · Atrial fibrillation 26% · Heart failure 24% · Depression 23% · Chronic kidney disease 21% · Cancer 18% · Stroke 8%.
The office billed $56,667, Medicare allowed $23,005 and paid $17,374; for 245 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 159 | 245 | 75 | 1.75 | $56,667 | $17,374 |
| 2023 | 140 | 246 | 72 | 1.85 | $43,933 | $11,285 |
| 2022 | 110 | 174 | 73 | 1.61 | $36,665 | $9,945 |
| 2021 | 107 | 237 | 72 | 1.64 | $97,713 | $22,669 |
| 2020 | 103 | 214 | 70 | 1.62 | $70,308 | $15,818 |
| 2019 | 116 | 283 | 72 | 2.04 | $78,402 | $17,759 |
| 2018 | 127 | 309 | 69 | 1.79 | $57,744 | $12,615 |
| 2017 | 160 | 405 | 69 | 2.03 | $116,607 | $21,005 |
| 2016 | 163 | 431 | 69 | 1.90 | $116,842 | $20,968 |
| 2015 | 141 | 352 | 68 | 1.79 | $105,962 | $21,176 |
| 2014 | 191 | 429 | 68 | 1.69 | $98,827 | $24,228 |
| 2013 | 199 | 491 | 70 | 1.94 | $125,765 | $33,206 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 64 | $6,485 | $86 |
| New patient visit (45+ min) | 12 | $1,399 | $117 |
| Test to determine lung volumes using sensors | 41 | $326 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $299 | $7 |
| Test to examine how well the lungs exchange gases | 45 | $264 | $6 |
2022: 5 services
| Return visit (30+ min) | 55 | $5,241 | $86 |
| New patient visit (45+ min) | 11 | $1,398 | $127 |
| Test to determine lung volumes using sensors | 24 | $224 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $210 | $8 |
| Test to examine how well the lungs exchange gases | 25 | $173 | $7 |
2021: 5 services
| Return visit (30+ min) | 41 | $4,179 | $89 |
| New patient visit (45+ min) | 14 | $1,991 | $142 |
| Test to determine lung volumes using sensors | 26 | $262 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 27 | $234 | $9 |
| Test to examine how well the lungs exchange gases | 25 | $185 | $7 |
2020: 5 services
| Return visit (30+ min) | 31 | $2,259 | $65 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $744 | $46 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $284 | $11 |
| Test to determine lung volumes using sensors | 26 | $269 | $10 |
| Test to examine how well the lungs exchange gases | 27 | $206 | $8 |
2019: 4 services
| Return visit (30+ min) | 33 | $2,575 | $70 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 48 | $479 | $10 |
| Test to determine lung volumes using sensors | 47 | $473 | $10 |
| Test to examine how well the lungs exchange gases | 46 | $350 | $7 |
2018: 4 services
| Return visit (30+ min) | 24 | $1,494 | $57 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 68 | $619 | $9 |
| Test to determine lung volumes using sensors | 57 | $506 | $9 |
| Test to examine how well the lungs exchange gases | 60 | $409 | $7 |
2017: 7 services
| Critical care, first 30-74 minutes | 12 | $8,266 | $184 |
| Return visit (30+ min) | 58 | $4,494 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $3,213 | $61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 68 | $727 | $11 |
| New patient visit (30+ min) | 13 | $725 | $56 |
| Test to determine lung volumes using sensors | 56 | $561 | $10 |
| Test to examine how well the lungs exchange gases | 63 | $467 | $7 |
2016: 7 services
| Return visit (30+ min) | 83 | $8,087 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $3,149 | $61 |
| New patient visit (30+ min) | 19 | $1,165 | $61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 60 | $636 | $10 |
| Test to examine how well the lungs exchange gases | 57 | $440 | $8 |
| Test to determine lung volumes using gas dilution or washout | 29 | $297 | $10 |
| Test to determine lung volumes using sensors | 21 | $219 | $10 |
2015: 6 services
| Return visit (30+ min) | 70 | $7,250 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,754 | $63 |
| New patient visit (30+ min) | 22 | $1,390 | $63 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $364 | $10 |
| Test to determine lung volumes using gas dilution or washout | 34 | $332 | $10 |
| Test to examine how well the lungs exchange gases | 34 | $246 | $7 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $9,296 | $64 |
| Return visit (30+ min) | 71 | $5,035 | $59 |
| Hospital discharge day management, more than 30 minutes | 29 | $2,852 | $95 |
| New patient visit (30+ min) | 29 | $1,857 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $340 | $10 |
| Test to determine lung volumes using gas dilution or washout | 29 | $276 | $10 |
| Test to examine how well the lungs exchange gases | 29 | $204 | $7 |
2013: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $10,284 | $62 |
| Return visit (30+ min) | 71 | $5,440 | $57 |
| Hospital discharge day management, more than 30 minutes | 43 | $4,223 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,744 | $119 |
| New patient visit (30+ min) | 20 | $1,326 | $66 |
| Hospital observation care on day of discharge | 16 | $1,025 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | $230 | $11 |
| Test to determine lung volumes using gas dilution or washout | 15 | $173 | $12 |
| Test to examine how well the lungs exchange gases | 20 | $161 | $8 |
Medicaid work
$37,193 in 2024
Medicaid paid $37,193 for 1,363 billed services this clinician did in 2024, up to 48 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 109 | $10,948 |
| EVALUATION OF WHEEZING | 367 | $8,909 |
| Short return visit (20+ min) | 144 | $8,707 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 352 | $5,033 |
| Diffusing capacity | 353 | $3,399 |
| Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device | 14 | $197 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 24 | $0 |
| 2024 | 1,363 | 7 | 48 | $37,193 |
| 2023 | 1,317 | 6 | 43 | $25,150 |
| 2022 | 988 | 5 | 39 | $22,035 |
| 2021 | 661 | 4 | 33 | $13,458 |
| 2020 | 615 | 5 | 29 | $12,939 |
| 2019 | 1,097 | 5 | 29 | $23,094 |
| 2018 | 1,167 | 5 | 48 | $29,768 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 246 | $7,498 |
| EVALUATION OF WHEEZING | 342 | $7,467 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 320 | $4,203 |
| Return visit (30+ min) | 66 | $3,022 |
| Diffusing capacity | 330 | $2,960 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
2022
| Return visit (30+ min) | 161 | $7,305 |
| EVALUATION OF WHEEZING | 247 | $5,731 |
| Short return visit (20+ min) | 107 | $3,546 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 236 | $3,236 |
| Diffusing capacity | 237 | $2,218 |
2021
| Short return visit (20+ min) | 249 | $7,851 |
| EVALUATION OF WHEEZING | 131 | $2,710 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 140 | $1,719 |
| Diffusing capacity | 141 | $1,178 |
2020
| Short return visit (20+ min) | 213 | $7,195 |
| EVALUATION OF WHEEZING | 130 | $2,810 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 127 | $1,604 |
| Diffusing capacity | 128 | $1,102 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 17 | $228 |
2019
| Return visit (30+ min) | 154 | $6,941 |
| EVALUATION OF WHEEZING | 273 | $6,133 |
| Short return visit (20+ min) | 145 | $4,163 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 261 | $3,469 |
| Diffusing capacity | 264 | $2,386 |
2018
| Return visit (30+ min) | 339 | $15,849 |
| EVALUATION OF WHEEZING | 284 | $6,691 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 238 | $3,338 |
| Diffusing capacity | 260 | $2,448 |
| Short return visit (20+ min) | 46 | $1,442 |
Drugs they prescribed that Part D paid
$519,545
Pharmacies billed $519,545 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 865) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
317 generic and 548 brand-name prescriptions · $519,545 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 147 | $177,583 | $1,208 |
| Combivent Respimat | 44 | $69,265 | $1,574 |
| Spiriva Respimat | 55 | $58,540 | $1,064 |
| Stiolto Respimat | 20 | $24,755 | $1,238 |
| Budesonide-Formoterol | 46 | $15,505 | $337 |
See all 20 drugs
| Trelegy Ellipta | 147 | $177,583 | $1,208 |
| Combivent Respimat | 44 | $69,265 | $1,574 |
| Spiriva Respimat | 55 | $58,540 | $1,064 |
| Stiolto Respimat | 20 | $24,755 | $1,238 |
| Budesonide-Formoterol | 46 | $15,505 | $337 |
| Albuterol Sulfate Hfa | 168 | $11,833 | $70 |
| Roflumilast | 19 | $10,050 | $529 |
| Incruse Ellipta | 24 | $9,301 | $388 |
| Breo Ellipta | 12 | $8,148 | $679 |
| Advair Hfa | 14 | $7,831 | $559 |
| Symbicort | 19 | $5,241 | $276 |
| Fluticasone-Salmeterol | 11 | $3,147 | $286 |
| Wixela Inhub | 16 | $1,748 | $109 |
| Montelukast | 46 | $1,100 | $24 |
| Fluticasone Propionate | 65 | $715 | $11 |
| Azelastine | 11 | $511 | $46 |
| Azithromycin | 12 | $288 | $24 |
| Omeprazole | 18 | $235 | $13 |
| Prednisone | 14 | $157 | $11 |
| Furosemide | 14 | $135 | $10 |
Year by year
| 2024 | 865 | 136 | 0% (0) | 63% | $519,545 |
| 2023 | 944 | 133 | None | 59% | $684,292 |
| 2022 | 965 | 124 | 0% (0) | 67% | $761,568 |
| 2021 | 1,017 | 118 | None | 70% | $533,606 |
| 2020 | 1,369 | 120 | None | 72% | $440,785 |
| 2019 | 1,642 | 143 | None | 79% | $633,867 |
| 2018 | 1,614 | 155 | 1% (13) | 81% | $619,659 |
| 2017 | 1,585 | 144 | None | 82% | $484,265 |
| 2016 | 1,414 | 144 | None | 81% | $322,156 |
| 2015 | 1,246 | 135 | 1% (12) | 81% | $286,041 |
| 2014 | 1,061 | 136 | 1% (12) | 75% | $204,259 |
| 2013 | 1,055 | 129 | 2% (19) | 79% | $176,983 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Ofev | 19 | $203,530 | $10,712 |
| Trelegy Ellipta | 105 | $160,295 | $1,527 |
| Spiriva Respimat | 81 | $91,686 | $1,132 |
| Symbicort | 101 | $58,495 | $579 |
| Combivent Respimat | 40 | $50,216 | $1,255 |
| Stiolto Respimat | 18 | $17,345 | $964 |
| Albuterol Sulfate Hfa | 129 | $11,750 | $91 |
| Wixela Inhub | 29 | $8,466 | $292 |
| Roflumilast | 11 | $7,717 | $702 |
| Ventolin Hfa | 37 | $4,270 | $115 |
| Fluticasone-Salmeterol | 17 | $3,448 | $203 |
| Montelukast | 56 | $1,381 | $25 |
| Fluticasone Propionate | 66 | $1,150 | $17 |
| Loperamide | 12 | $885 | $74 |
| Zafirlukast | 11 | $783 | $71 |
| Prednisone | 51 | $668 | $13 |
| Azithromycin | 26 | $664 | $26 |
| Omeprazole | 16 | $406 | $25 |
| Furosemide | 15 | $230 | $15 |
2022: 21 drugs
| Trelegy Ellipta | 78 | $129,765 | $1,664 |
| Spiriva Respimat | 73 | $84,466 | $1,157 |
| Symbicort | 114 | $81,148 | $712 |
| Combivent Respimat | 42 | $67,420 | $1,605 |
| Daliresp | 24 | $29,635 | $1,235 |
| Breztri Aerosphere | 12 | $16,736 | $1,395 |
| Spiriva Handihaler | 21 | $16,684 | $794 |
| Atrovent Hfa | 16 | $16,481 | $1,030 |
| Advair Diskus | 13 | $13,266 | $1,020 |
| Albuterol Sulfate Hfa | 149 | $13,103 | $88 |
| Breo Ellipta | 11 | $12,008 | $1,092 |
| Incruse Ellipta | 16 | $11,467 | $717 |
| Fluticasone-Salmeterol | 28 | $9,172 | $328 |
| Wixela Inhub | 18 | $8,790 | $488 |
| Ventolin Hfa | 47 | $6,247 | $133 |
| Montelukast | 61 | $1,759 | $29 |
| Prednisone | 41 | $951 | $23 |
| Fluticasone Propionate | 46 | $891 | $19 |
| Omeprazole | 12 | $309 | $26 |
| Furosemide | 15 | $238 | $16 |
| Azithromycin | 21 | $191 | $9 |
2021: 20 drugs
| Symbicort | 146 | $95,846 | $656 |
| Spiriva Respimat | 85 | $69,152 | $814 |
| Combivent Respimat | 59 | $55,800 | $946 |
| Spiriva | 45 | $34,776 | $773 |
| Daliresp | 24 | $27,813 | $1,159 |
| Trelegy Ellipta | 18 | $22,186 | $1,233 |
| Advair Diskus | 18 | $18,136 | $1,008 |
| Atrovent Hfa | 16 | $17,766 | $1,110 |
| Incruse Ellipta | 32 | $16,810 | $525 |
| Albuterol Sulfate Hfa | 155 | $14,549 | $94 |
| Wixela Inhub | 18 | $10,400 | $578 |
| Fluticasone-Salmeterol | 24 | $7,990 | $333 |
| Ventolin Hfa | 60 | $7,943 | $132 |
| Montelukast | 49 | $1,399 | $29 |
| Fluticasone Propionate | 57 | $1,041 | $18 |
| Levalbuterol Tartrate Hfa | 14 | $960 | $69 |
| Prednisone | 65 | $953 | $15 |
| Furosemide | 14 | $239 | $17 |
| Azithromycin | 15 | $157 | $10 |
| Omeprazole | 17 | $103 | $6 |
2020: 24 drugs
| Symbicort | 212 | $105,700 | $499 |
| Spiriva Respimat | 118 | $62,199 | $527 |
| Spiriva | 94 | $49,685 | $529 |
| Daliresp | 47 | $31,190 | $664 |
| Atrovent Hfa | 55 | $29,585 | $538 |
| Combivent Respimat | 49 | $25,949 | $530 |
| Advair Diskus | 17 | $16,430 | $966 |
| Albuterol Sulfate Hfa | 167 | $11,450 | $69 |
| Wixela Inhub | 37 | $11,017 | $298 |
| Budesonide-Formoterol | 24 | $7,169 | $299 |
| Ventolin Hfa | 87 | $6,638 | $76 |
| Incruse Ellipta | 18 | $6,406 | $356 |
| Qvar Redihaler | 12 | $3,599 | $300 |
| Fluticasone-Salmeterol | 20 | $3,580 | $179 |
| Accolate | 12 | $3,185 | $265 |
| Proair Hfa | 27 | $2,788 | $103 |
| Levalbuterol Tartrate Hfa | 15 | $1,026 | $68 |
| Prednisone | 92 | $1,016 | $11 |
| Fluticasone Propionate | 49 | $936 | $19 |
| Montelukast | 65 | $816 | $13 |
| Theophylline | 19 | $669 | $35 |
| Azithromycin | 24 | $367 | $15 |
| Furosemide | 15 | $172 | $11 |
| Omeprazole | 19 | $140 | $7 |
2019: 24 drugs
| Esbriet | 19 | $188,753 | $9,934 |
| Symbicort | 331 | $136,445 | $412 |
| Spiriva | 117 | $60,142 | $514 |
| Spiriva Respimat | 113 | $49,214 | $436 |
| Combivent Respimat | 94 | $46,283 | $492 |
| Advair Diskus | 50 | $28,623 | $572 |
| Atrovent Hfa | 57 | $27,770 | $487 |
| Incruse Ellipta | 49 | $18,641 | $380 |
| Daliresp | 38 | $18,425 | $485 |
| Ventolin Hfa | 152 | $10,300 | $68 |
| Proair Hfa | 132 | $9,591 | $73 |
| Wixela Inhub | 33 | $6,872 | $208 |
| Breo Ellipta | 15 | $5,490 | $366 |
| Qvar Redihaler | 11 | $4,208 | $383 |
| Fluticasone-Salmeterol | 11 | $1,966 | $179 |
| Albuterol Sulfate Hfa | 36 | $1,690 | $47 |
| Montelukast | 57 | $1,140 | $20 |
| Prednisone | 84 | $878 | $10 |
| Theophylline | 12 | $722 | $60 |
| Azelastine | 14 | $572 | $41 |
| Fluticasone Propionate | 38 | $447 | $12 |
| Azithromycin | 32 | $267 | $8 |
| Omeprazole | 31 | $164 | $5 |
| Furosemide | 31 | $122 | $4 |
2018: 22 drugs
| Esbriet | 21 | $195,761 | $9,322 |
| Symbicort | 309 | $115,084 | $372 |
| Advair Diskus | 130 | $66,326 | $510 |
| Spiriva | 146 | $65,533 | $449 |
| Spiriva Respimat | 101 | $43,499 | $431 |
| Atrovent Hfa | 77 | $33,388 | $434 |
| Combivent Respimat | 67 | $30,183 | $450 |
| Daliresp | 33 | $12,398 | $376 |
| Proair Hfa | 143 | $9,260 | $65 |
| Ventolin Hfa | 140 | $9,045 | $65 |
| Incruse Ellipta | 22 | $7,230 | $329 |
| Qvar Redihaler | 11 | $3,354 | $305 |
| Accolate | 12 | $2,764 | $230 |
| Flovent Diskus | 12 | $2,224 | $185 |
| Proventil Hfa | 14 | $1,616 | $115 |
| Montelukast | 47 | $897 | $19 |
| Omeprazole | 59 | $689 | $12 |
| Fluticasone Propionate | 40 | $588 | $15 |
| Prednisone | 63 | $374 | $6 |
| Metolazone | 12 | $269 | $22 |
| Furosemide | 42 | $140 | $3 |
| Azithromycin | 12 | $90 | $8 |
2017: 20 drugs
| Symbicort | 330 | $106,937 | $324 |
| Esbriet | 13 | $105,328 | $8,102 |
| Advair Diskus | 145 | $66,042 | $455 |
| Spiriva | 161 | $62,955 | $391 |
| Atrovent Hfa | 113 | $40,836 | $361 |
| Combivent Respimat | 75 | $26,840 | $358 |
| Daliresp | 44 | $14,366 | $327 |
| Spiriva Respimat | 32 | $12,625 | $395 |
| Proair Hfa | 167 | $10,590 | $63 |
| Ventolin Hfa | 92 | $5,704 | $62 |
| Incruse Ellipta | 13 | $4,424 | $340 |
| Qvar | 14 | $3,320 | $237 |
| Accolate | 12 | $2,786 | $232 |
| Proventil Hfa | 24 | $2,298 | $96 |
| Montelukast | 46 | $793 | $17 |
| Fluticasone Propionate | 64 | $771 | $12 |
| Omeprazole | 56 | $682 | $12 |
| Azithromycin | 22 | $313 | $14 |
| Prednisone | 48 | $242 | $5 |
| Furosemide | 30 | $90 | $3 |
2016: 18 drugs
| Symbicort | 294 | $92,464 | $315 |
| Spiriva | 196 | $71,903 | $367 |
| Advair Diskus | 149 | $59,757 | $401 |
| Atrovent Hfa | 104 | $31,852 | $306 |
| Combivent Respimat | 70 | $24,186 | $346 |
| Proair Hfa | 159 | $9,369 | $59 |
| Incruse Ellipta | 16 | $5,271 | $329 |
| Qvar | 22 | $5,078 | $231 |
| Daliresp | 16 | $4,840 | $303 |
| Accolate | 12 | $2,842 | $237 |
| Ventolin Hfa | 47 | $2,620 | $56 |
| Proventil Hfa | 14 | $1,232 | $88 |
| Fluticasone Propionate | 80 | $1,120 | $14 |
| Montelukast | 52 | $692 | $13 |
| Omeprazole | 38 | $255 | $7 |
| Prednisone | 34 | $231 | $7 |
| Azithromycin | 22 | $184 | $8 |
| Furosemide | 32 | $81 | $3 |
2015: 16 drugs
| Symbicort | 250 | $72,861 | $291 |
| Spiriva | 165 | $56,325 | $341 |
| Advair Diskus | 142 | $50,928 | $359 |
| Combivent Respimat | 72 | $23,708 | $329 |
| Atrovent Hfa | 84 | $22,299 | $265 |
| Proair Hfa | 185 | $10,682 | $58 |
| Daliresp | 21 | $5,631 | $268 |
| Accolate | 13 | $2,843 | $219 |
| Qvar | 14 | $2,344 | $167 |
| Ventolin Hfa | 12 | $574 | $48 |
| Omeprazole | 47 | $496 | $11 |
| Montelukast | 27 | $449 | $17 |
| Azithromycin | 23 | $421 | $18 |
| Fluticasone Propionate | 30 | $336 | $11 |
| Prednisone | 29 | $159 | $5 |
| Furosemide | 21 | $43 | $2 |
2014: 20 drugs
| Advair Diskus | 143 | $46,556 | $326 |
| Symbicort | 148 | $40,861 | $276 |
| Spiriva | 122 | $36,482 | $299 |
| Combivent Respimat | 56 | $18,086 | $323 |
| Atrovent Hfa | 39 | $9,541 | $245 |
| Proair Hfa | 146 | $7,784 | $53 |
| Daliresp | 29 | $7,181 | $248 |
| Qvar | 19 | $2,883 | $152 |
| Accolate | 12 | $1,428 | $119 |
| Ventolin Hfa | 28 | $1,268 | $45 |
| Proventil Hfa | 11 | $992 | $90 |
| Omeprazole | 43 | $677 | $16 |
| Fluticasone Propionate | 38 | $670 | $18 |
| Montelukast | 16 | $497 | $31 |
| Azithromycin | 15 | $201 | $13 |
| Theophylline Anhydrous | 16 | $197 | $12 |
| Prednisone | 28 | $130 | $5 |
| Furosemide | 18 | $51 | $3 |
| Lisinopril | 13 | $45 | $3 |
| Allopurinol | 11 | $38 | $3 |
2013: 19 drugs
| Advair Diskus | 184 | $55,799 | $303 |
| Spiriva | 124 | $37,838 | $305 |
| Symbicort | 94 | $24,777 | $264 |
| Proair Hfa | 175 | $9,397 | $54 |
| Atrovent Hfa | 39 | $8,907 | $228 |
| Daliresp | 35 | $7,243 | $207 |
| Combivent | 26 | $5,842 | $225 |
| Combivent Respimat | 13 | $4,495 | $346 |
| Qvar | 22 | $3,182 | $145 |
| Ventolin Hfa | 36 | $1,527 | $42 |
| Accolate | 11 | $1,309 | $119 |
| Proventil Hfa | 15 | $937 | $62 |
| Fluticasone Propionate | 35 | $901 | $26 |
| Montelukast | 13 | $662 | $51 |
| Theophylline Anhydrous | 35 | $408 | $12 |
| Azithromycin | 13 | $117 | $9 |
| Prednisone | 29 | $91 | $3 |
| Furosemide | 18 | $63 | $3 |
| Allopurinol | 13 | $52 | $4 |
Money from drug and device companies
$279 in 2025
| 2025 | 2 | 2 | $200 | $279 |
| 2024 | 3 | 3 | $200 | $447 |
| 2023 | 2 | 2 | $200 | $263 |
| 2022 | 1 | 2 | None | $77 |
| 2019 | 3 | 3 | None | $187 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| Sanofi-Aventis U.S. | Dupixent | $79 | 1 payment
|
See all 2 published payments
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-09-30 | Adempas | $200 |
| Sanofi-Aventis U.S. | Education · 2025-08-29 | Dupixent | $79 |
See earlier years (2024, 2023, 2022, 2019)
2024: $447
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $125 | 1 payment
|
| Genzyme | Dupixent | $122 | 1 payment
|
2023: $263
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| Amgen | Tezspire | $63 | 1 payment
|
2022: $77
| Regeneron Healthcare Solutions | Dupixent | $77 | 2 payments
|
2019: $187
| GlaxoSmithKline | Trelegy Ellipta | $122 | 1 payment
|
| Genentech USA | Esbriet | $38 | 1 payment
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $28 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447330725
- Licence
- CA A61568California A61568: Current · expires 2029-01-31
- Group
- Stanford Health Care · County of San Mateo
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A615680
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-17
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 222 W 39th Ave, San Mateo, CA, 94403